Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer,
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …
Treatment of epithelial ovarian cancer
L Kuroki, SR Guntupalli - Bmj, 2020 - bmj.com
Ovarian cancer is the third most common gynecologic malignancy worldwide but accounts
for the highest mortality rate among these cancers. A stepwise approach to assessment …
for the highest mortality rate among these cancers. A stepwise approach to assessment …
Randomized trial of cytoreductive surgery for relapsed ovarian cancer
Background Treatment for patients with recurrent ovarian cancer has been mainly based on
systemic therapy. The role of secondary cytoreductive surgery is unclear. Methods We …
systemic therapy. The role of secondary cytoreductive surgery is unclear. Methods We …
Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology
DK Armstrong, RD Alvarez, JN Bakkum-Gamez… - Journal of the National …, 2021 - jnccn.org
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the
United States and is the country's fifth most common cause of cancer mortality in women. A …
United States and is the country's fifth most common cause of cancer mortality in women. A …
[HTML][HTML] Updates and new options in advanced epithelial ovarian cancer treatment
Financial Disclosure Ernst Lengyel disclosed that money was paid to his institution from
AbbVie (funding preclinical studies), NCI (RO1 grants), and the Ovarian Cancer Research …
AbbVie (funding preclinical studies), NCI (RO1 grants), and the Ovarian Cancer Research …
[HTML][HTML] The forefront of ovarian cancer therapy: update on PARP inhibitors
MR Mirza, RL Coleman, A González-Martín… - Annals of …, 2020 - Elsevier
Background In recurrent ovarian cancer, poly (ADP-ribose) polymerase (PARP)-inhibiting
agents have transformed the treatment of platinum-sensitive disease. New data support use …
agents have transformed the treatment of platinum-sensitive disease. New data support use …
[HTML][HTML] Epithelial ovarian cancer
S Sambasivan - Cancer Treatment and Research Communications, 2022 - Elsevier
Epithelial ovarian cancer is the second commonest cause of death amongst all
gynaecological cancers. Treatment is challenging because almost 75% of cases are …
gynaecological cancers. Treatment is challenging because almost 75% of cases are …
Heterogeneity and treatment landscape of ovarian carcinoma
AC Veneziani, E Gonzalez-Ochoa, H Alqaisi… - Nature Reviews …, 2023 - nature.com
Ovarian carcinoma is characterized by heterogeneity at the molecular, cellular and
anatomical levels, both spatially and temporally. This heterogeneity affects response to …
anatomical levels, both spatially and temporally. This heterogeneity affects response to …
[HTML][HTML] Pretransplant solid organ malignancy and organ transplant candidacy: a consensus expert opinion statement
Patients undergoing evaluation for solid organ transplantation (SOT) often have a history of
malignancy. Although the cancer has been treated in these patients, the benefits of …
malignancy. Although the cancer has been treated in these patients, the benefits of …
[HTML][HTML] Extracellular matrix in high-grade serous ovarian cancer: Advances in understanding of carcinogenesis and cancer biology
High-grade serous ovarian cancer (HGSOC) is notoriously known as the “silent killer” of post-
menopausal women as it has an insidious progression and is the deadliest gynaecological …
menopausal women as it has an insidious progression and is the deadliest gynaecological …